Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henriette Roed Nielsen

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Ugeskrift for Laeger|September 1, 2006
[Blood samples with hemolysis: clinical consequences?]Mads Nybo, Henriette Roed Nielsen, Annebirthe Bo Hansen
Acta Oncologica (Stockholm, Sweden)|September 12, 2015
Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2Henriette Roed Nielsen, Janne Petersen, Christina Therkildsen, et al.
Familial Cancer|March 9, 2016
No evidence of increased breast cancer risk for proven noncarriers from BRCA1 and BRCA2 familiesHenriette Roed Nielsen, Janne Petersen, Lotte Krogh, et al.
European Journal of Human Genetics : EJHG|January 7, 2016
Post-mortem testing; germline BRCA1/2 variant detection using archival FFPE non-tumor tissue. A new paradigm in genetic counselingAnnabeth Høgh Petersen, Mads Malik Aagaard, Henriette Roed Nielsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2022
Reply to V. Fallet et alShuai Li, Valentina Silvestri, Timothy R Rebbeck, et al.
Familial Cancer|February 3, 2016
BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish populationHenriette Roed Nielsen, Mef Nilbert, Janne Petersen, et al.
Breast Cancer Research : BCR|June 14, 2023
Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAnessLars V B Andersen, Martin J Larsen, Helen Davies, et al.
Breast Cancer Research : BCR|January 9, 2024
Male with an apparently normal phenotype carrying a BRCA1 exon 20 duplication in trans to a BRCA1 frameshift variantInes Block, Àngels Mateu-Regué, Thi Tuyet Nhu Do, et al.
Oncotarget|May 1, 2018
Full in-frame exon 3 skipping of <i>BRCA2</i> confers high risk of breast and/or ovarian cancerSandrine M Caputo, Mélanie Léone, Francesca Damiola, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2022
Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic VariantsShuai Li, Valentina Silvestri, Goska Leslie, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Ugeskrift for Laeger|September 1, 2006
[Blood samples with hemolysis: clinical consequences?]Mads Nybo, Henriette Roed Nielsen, Annebirthe Bo Hansen
Acta Oncologica (Stockholm, Sweden)|September 12, 2015
Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2Henriette Roed Nielsen, Janne Petersen, Christina Therkildsen, et al.
Familial Cancer|March 9, 2016
No evidence of increased breast cancer risk for proven noncarriers from BRCA1 and BRCA2 familiesHenriette Roed Nielsen, Janne Petersen, Lotte Krogh, et al.
European Journal of Human Genetics : EJHG|January 7, 2016
Post-mortem testing; germline BRCA1/2 variant detection using archival FFPE non-tumor tissue. A new paradigm in genetic counselingAnnabeth Høgh Petersen, Mads Malik Aagaard, Henriette Roed Nielsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2022
Reply to V. Fallet et alShuai Li, Valentina Silvestri, Timothy R Rebbeck, et al.
Familial Cancer|February 3, 2016
BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish populationHenriette Roed Nielsen, Mef Nilbert, Janne Petersen, et al.
Breast Cancer Research : BCR|June 14, 2023
Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAnessLars V B Andersen, Martin J Larsen, Helen Davies, et al.
Breast Cancer Research : BCR|January 9, 2024
Male with an apparently normal phenotype carrying a BRCA1 exon 20 duplication in trans to a BRCA1 frameshift variantInes Block, Àngels Mateu-Regué, Thi Tuyet Nhu Do, et al.
Oncotarget|May 1, 2018
Full in-frame exon 3 skipping of <i>BRCA2</i> confers high risk of breast and/or ovarian cancerSandrine M Caputo, Mélanie Léone, Francesca Damiola, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2022
Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic VariantsShuai Li, Valentina Silvestri, Goska Leslie, et al.
Pageof 2